TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma

Sandy Tretbar; Peter Krausbeck; Anja Müller; Michael Friedrich; Christoforos Vaxevanis; Juergen Bukur; Simon Jasinski-Bergner; Barbara Seliger

doi:10.18632/oncotarget.26682

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma

Sandy Tretbar _, Peter Krausbeck, Anja Müller, Michael Friedrich, Christoforos Vaxevanis, Juergen Bukur, Simon Jasinski-Bergner and Barbara Seliger

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2019; 10:1507-1524. https://doi.org/10.18632/oncotarget.26682

Metrics: PDF 1687 views | Full Text 3471 views | ?

Abstract

Sandy Tretbar1,*, Peter Krausbeck1,2,*, Anja Müller1, Michael Friedrich1, Christoforos Vaxevanis1, Juergen Bukur1, Simon Jasinski-Bergner1 and Barbara Seliger1

1Martin Luther University Halle-Wittenberg, Institute for Medical Immunology, 06112 Halle, Germany

2State Hospital, Healthcare Centre Glantal, 55590 Meisenheim, Germany

*These authors contributed equally to this work

Correspondence to:

Barbara Seliger, email: [email protected]

Keywords: epithelial-to-mesenchymal transition; renal cell carcinoma; TGF-β; Smad-signaling pathway; inhibition

Received: September 21, 2018 Accepted: February 01, 2019 Published: February 19, 2019

ABSTRACT

Epithelial-to-mesenchymal transition (EMT) is a crucial step in cancer progression and the number one reason for poor prognosis and worse overall survival of patients. Although this essential process has been widely studied in many solid tumors as e.g. melanoma and breast cancer, more detailed research in renal cell carcinoma (RCC) is required, especially for the major EMT-inducer transforming growth factor beta (TGF-β). Here, we provide a study of six different RCC cell lines of two different RCC subtypes and their response to recombinant TGF-β1 treatment. We established a model system shifting the cells to a mesenchymal cell type without losing their mesenchymal character even in the absence of the external stimulus. This model system forms a solid basis for future studies of the EMT process in RCCs to better understand the molecular basis of this process responsible for cancer progression.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26682

Publication Alerts

Research Papers:

TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma

Abstract